ClinicalTrials.gg
RecruitingNCT07924839Updated Nov 9, 2026

PM2.5 Exposure, Obesity, and Cardiovascular Health

An interventional study of Air filtration systems without filters (sham) in Cardiovascular (CV) Risk, sponsored by Michigan State University. Recruiting at 1 site in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Michigan State University · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Jun 2025, registered Jun 2026).
  • Started Jun 2025; still recruiting 1 year 4 months later.
Updated Nov 9, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

Obesity and exposure to fine particulate matter (particles of aerodynamic diameter less than 2.5 µm, PM2.5) air pollution are established risk factors for cardiovascular (CV) morbidity and mortality. This proposed pilot project seeks to assess interactions between PM2.5 exposure, obesity, CV health, and dietary antioxidant in subjects with obesity.

Read the detailed description

This proposed intervention study will investigate (1) whether the use of portable air filtration systems (PAFS), by lowering PM2.5 exposures, will improve CV risk factors in subjects with obesity; and (2) whether antioxidant levels will modify the association between PM2.5 exposure and blood pressure. Our project will help validate the benefits of novel strategies to employ PAFS. Positive results would represent a key step in forming the evidence base required to promote more wide-scale PAFS use; in the long term, given their low cost and burden, PAFS use could be up-scaled to help protect diverse populations.

02

Conditions studied

  • Cardiovascular (CV) Risk
03

In context

Lead sponsor

Michigan State University is the lead sponsor of 143 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥21 years old
  • diagnosis of hypertension (BP ≥140/90 mm Hg)
  • obesity (>30)

Exclusion criteria

Exclusion Criteria:

  • any CV event (myocardial infarction, stroke, heart failure) in the past 3 months
  • unstable CV condition (class 3-4 angina or heart failure) or any medical condition that would place the subject at risk from participation or jeopardize study integrity (per investigators)
  • expected overnight travel outside their home during the 9-week study period
  • unable to comprehend/sign
  • lung disease requiring oxygen
  • cancer receiving active treatment or chemotherapy
  • CPAP use for sleep apnea
  • CV medication change in the prior month
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Sham comparator
    Arm 1

    Participants are exposed to unfiltered air (sham) via air filtration systems in the bedroom and main living space of each residence.

    Device: Air filtration systems without filters (sham)

  • Active comparator
    Arm 2

    Participants were exposed to high-efficiency (HEPA) filtered air via air filtration systems in the bedroom and main living space of each residence.

    Device: Air filtration systems without filters (sham)

Interventions

  • DeviceAir filtration systems without filters (sham)

    Subjects were exposed to high-efficiency filtered air.

06

What researchers measure

Primary outcomes

  1. Brachial blood pressure

    Time frame: Daily for 28 days, between 8-10 AM, starting 24 hours after air filtration systems are placed

Secondary outcomes

  1. C-reactive protein

    Blood samples for inflammatory marker (high-sensitivity C-reactive protein)

    Time frame: Day 1 and Day 28 of each 4-week intervention period.

  2. Carotenoid

    non-invasive optical measurement of skin carotenoid levels

    Time frame: Day 1 and Day 28 of each 4-week intervention period.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Oct 2026, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2026
First posted
Nov 9, 2026
StartActual
Jun 18, 2025
Primary completionEst.
Oct 31, 2026
CompletionEst.
Jan 31, 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07924839
Responsible party
Masako Morishita (Associate Professor, Michigan State University) — Principal investigator
First posted
Nov 9, 2026
Start date
Jun 18, 2025
Primary completion
Oct 31, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Nov 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion